Evidence map›Paper›PMID 36896021›Full record

ArticlebioRxiv : the preprint server for biology2023

Antibody landscape of C57BL/6 mice cured of B78 melanoma via immunotherapy.

A Hoefges, S J McIlwain, A K Erbe, N Mathers, A Xu, D Melby, K Tetreault, T Le, K Kim, R S Pinapati and 9 more

Open access · greenAbstract readPreprint
In one paragraph

Article in bioRxiv : the preprint server for biology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 3 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

19 authors at 1 institution in 1 country.

A HoefgesDepartment of Human Oncology, University of Wisconsin, Madison, WI, USA.
S J McIlwainDepartment of Biostatistics and Medical Informatics, University of Wisconsin, Madison, WI, USA.
A K ErbeDepartment of Human Oncology, University of Wisconsin, Madison, WI, USA.
N MathersDepartment of Human Oncology, University of Wisconsin, Madison, WI, USA.
A XuDepartment of Human Oncology, University of Wisconsin, Madison, WI, USA.
D MelbyDepartment of Human Oncology, University of Wisconsin, Madison, WI, USA.
K TetreaultDepartment of Biostatistics and Medical Informatics, University of Wisconsin, Madison, WI, USA.
T LeDepartment of Biostatistics and Medical Informatics, University of Wisconsin, Madison, WI, USA.
K KimDepartment of Biostatistics and Medical Informatics, University of Wisconsin, Madison, WI, USA.
R S PinapatiNimble Therapeutics, Inc., Madison, WI, USA.
B GarciaNimble Therapeutics, Inc., Madison, WI, USA.
J PatelNimble Therapeutics, Inc., Madison, WI, USA.
M HeckDepartment of Human Oncology, University of Wisconsin, Madison, WI, USA.
A S FeilsDepartment of Human Oncology, University of Wisconsin, Madison, WI, USA.
N TsarovskyDepartment of Human Oncology, University of Wisconsin, Madison, WI, USA.
J A HankDepartment of Human Oncology, University of Wisconsin, Madison, WI, USA.
Z S MorrisDepartment of Human Oncology, University of Wisconsin, Madison, WI, USA.
I M OngDepartment of Biostatistics and Medical Informatics, University of Wisconsin, Madison, WI, USA.
P M SondelDepartment of Human Oncology, University of Wisconsin, Madison, WI, USA.
University of Wisconsin–Madison · US

Funding

UW COMPREHENSIVE CANCER CENTER SUPPORTP30CA014520 · NCI · UNIVERSITY OF WISCONSIN-MADISON · PI Justine Yang Bruce · 1985 to 2026
$142.6M
University of Wisconsin Institute for Clinical and Translational ResearchUL1TR002373 · NCATS · UNIVERSITY OF WISCONSIN-MADISON · PI ELIZABETH S BURNSIDE, Allan R. Brasier · 2017 to 2026
$75.9M
Wisconsin Infant Study Cohort (WISC)U19AI104317 · NIAID · UNIVERSITY OF WISCONSIN-MADISON · PI CHRISTINE Marie SEROOGY · 2013 to 2026
$22.5M
Understanding and Overcoming Resistance to Immunotherapies in Childhood CancersU54CA232568 · NCI · CHILDREN'S HOSP OF PHILADELPHIA · PI MACKALL, CRYSTAL, MARIS, JOHN M · 2018 to 2022
$13.1M
Project 3: Modulation of the head and neck tumor immune microenvironment by targeting the TAM family of receptorsP50CA278595 · NCI · UNIVERSITY OF WISCONSIN-MADISON · PI David J Beebe · 2022 to 2026
$12.5M
Radionuclide Production and Radiochemistry Core Description CoreP01CA250972 · NCI · UNIVERSITY OF WISCONSIN-MADISON · PI BEDNARZ, BRYAN PATRICK · 2020 to 2024
$12.5M
Institutional Career Development CoreKL2TR002374 · NCATS · UNIVERSITY OF WISCONSIN-MADISON · PI Bo Liu, Marin Leigh Schweizer · 2017 to 2026
$9.7M
Enhancing Antibody-directed Innate Immunity to Improve Cancer OutcomeR35CA197078 · NCI · UNIVERSITY OF WISCONSIN-MADISON · PI SONDEL, PAUL M · 2015 to 2021
$6.4M
Immunomodulation of the Tumor Microenvironment with Molecular Targeted Radiotherapy to Facilitate an Adaptive Anti-Tumor Immune Response to Combined Modality ImmunotherapiesU01CA233102 · NCI · UNIVERSITY OF WISCONSIN-MADISON · PI MORRIS, ZACHARY SCOTT, WEICHERT, JAMEY P · 2018 to 2022
$4.0M
NCATS NIH HHS KL2 TR002374NCATS NIH HHS UL1 TR002373NCI NIH HHS P01 CA250972NCI NIH HHS P30 CA014520NCI NIH HHS R35 CA197078NCI NIH HHS U01 CA233102NCI NIH HHS U54 CA232568NIAID NIH HHS U19 AI104317
6 · The paper itself

Abstract

Hoefges et al. utilized a whole-proteome peptide array approach to show that C57BL/6 mice develop a large repertoire of antibodies against linear peptide sequences of their melanoma after receiving a curative immunotherapy regimen consisting of radiation and an immunocytokine. Antibodies can play an important role in innate and adaptive immune responses against cancer, and in preventing infectious disease. Flow cytometry analysis of sera of immune mice that were previously cured of their melanoma through a combined immunotherapy regimen with long-term memory showed strong antibody-binding against melanoma tumor cell lines. Using a high-density whole-proteome peptide array, we assessed potential protein-targets for antibodies found in immune sera. Sera from 6 of these cured mice were analyzed with this high-density, whole-proteome peptide array to determine specific antibody-binding sites and their linear peptide sequence. We identified thousands of peptides that were targeted by 2 or more of these 6 mice and exhibited strong antibody binding only by immune, not naive sera. Confirmatory studies were done to validate these results using 2 separate ELISA-based systems. To the best of our knowledge, this is the first study of the "immunome" of protein-based epitopes that are recognized by immune sera from mice cured of cancer via immunotherapy.

Indexed as

antibodycancerhigh-density peptide arrayin situ vaccinemelanomaproteomeradio-immunotherapy

Identifiers

PMID36896021
PMCPMC9996675
OpenAlexW4322009004

What OpenQuestion holds

Textmetadata
LicenceCC BY-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.